Marijuana Rescheduling In Peril: AMA Demands FDA Scientific Standards As GAO Report Exposes Malaise

MMJ International Holdings CEO Duane Boise said an October 28 American Medical Association letter and findings from the congressional watchdog GAO raise fundamental questions about federal marijuana rescheduling and authorization of non-FDA-approved marijuana products. The article provides no further details on the findings, proposed actions, or market response.